The content on this site is intended for healthcare professionals only
Prof Robin Foà talks to ecancer ahead of his talk at the ALL Assembly 2021.
He begins by explaining that through modern day diagnostic approaches we can identify lineage affiliation of all cases of ALL. Through diagnostic workup we've learned to identify sub-groups of ALL, such as Philadelphia chromosome-positive ALL (Ph+ ALL), particularly in adults.
Prof Foà then goes on to talk about CAR T-cells and how they've opened up a new window of opportunity in ALL and immuno-therapeutic strategies that have and are becoming a reality in the treatment of ALL.
He concludes by talking about study groups and networks, touching on the laboratory testing process in Rome and acknowledges that these testing conditions are not available in every country, especially where there are limited accessibility to not only drugs, but technology as well.
New classification for identifying HR myeloma based on cytogenetic abnormalities
SABCS 2023: Latest breast cancer diagnostics guidelines
Choosing Wisely in radiology Tanzania
Why tumour markers are not recommended as screening tests
Choosing Wisely to mitigate financial toxicity in cancer care in Africa
Digital rectal examination is not useful as a solitary screening tool for prostate cancer in young men
Tomosynthesis guided biopsy
Evidence-based approach to lymph node assessment and targeted axillary dissection
Genetic profiling identifies patients who can omit radiation therapy after breast-conserving surgery
